dipyridamole Side Effects
Also known as: Persantine
Analysis of 3,682 adverse event reports submitted to the FDA from 2002 to 2025.
Total Reports
3,682
Death-Related
459
12.5% of reports
Hospitalizations
1,894
51.4% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 459 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 73 |
| PNEUMONIA | 37 |
| CEREBRAL HAEMORRHAGE | 29 |
| CEREBROVASCULAR ACCIDENT | 29 |
| RENAL FAILURE | 27 |
| MULTI-ORGAN FAILURE | 25 |
| SEPSIS | 25 |
| EMBOLISM | 22 |
| DRUG INEFFECTIVE | 20 |
| DIARRHOEA | 19 |
| NEUROLOGICAL SYMPTOM | 19 |
| HAEMORRHAGE INTRACRANIAL | 18 |
| HYPOTENSION | 18 |
| MYOCARDIAL INFARCTION | 18 |
| NEUTROPENIC SEPSIS | 18 |
| DYSPNOEA | 17 |
| GASTROINTESTINAL HAEMORRHAGE | 17 |
| HAEMORRHAGE | 17 |
| NAUSEA | 17 |
| ANAEMIA | 16 |
Reactions in Hospitalization Reports
Top reactions in 1,894 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| FALL | 525 |
| HYPOTENSION | 484 |
| COGNITIVE DISORDER | 479 |
| PAIN | 462 |
| DEPRESSED LEVEL OF CONSCIOUSNESS | 459 |
| ORTHOSTATIC HYPOTENSION | 456 |
| CONSTIPATION | 455 |
| BALANCE DISORDER | 449 |
| SEDATION COMPLICATION | 446 |
| BLOOD CALCIUM DECREASED | 435 |
| CREATININE RENAL CLEARANCE DECREASED | 435 |
| MOBILITY DECREASED | 430 |
| SEDATION | 425 |
| TOXICITY TO VARIOUS AGENTS | 366 |
| DYSPNOEA | 170 |
| DRUG INTERACTION | 133 |
| OFF LABEL USE | 102 |
| VOMITING | 82 |
| CEREBROVASCULAR ACCIDENT | 77 |
| PRODUCT USE IN UNAPPROVED INDICATION | 75 |
Nearby — Related Medications
What the FAERS Data Reveals About dipyridamole Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 3,682 voluntary reports linked to dipyridamole and its brand equivalents (Persantine), spanning 2002 through 2025. Of those, 459 (12.5%) listed death as an outcome and 1,894 (51.4%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 53% were female and 46% male; age distribution skews toward 75+, with 1,235 reports in that bracket. The single most reported reaction is fall with 545 submissions, followed by hypotension and pain.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.